Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

8.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.7K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.7K
Production of Formed Elements01:34

Production of Formed Elements

3.5K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
3.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Genomic and transcriptomic differences between neuroendocrine neoplasms and carcinomas with human papillomavirus (HPV).

Infectious agents and cancer·2026
Same author

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

American journal of hematology·2026
Same author

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Dec 28, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.8K

Clonal hematopoiesis in cancer.

Soo J Park1, Rafael Bejar1

  • 1Moores Cancer Center, University of California San Diego, La Jolla, CA.

Experimental Hematology
|February 12, 2020
PubMed
Summary

Clonal hematopoiesis, a premalignant condition, increases myeloid neoplasm risk in cancer patients. Understanding its mechanisms can improve surveillance and targeted therapies for this vulnerable group.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Clonal hematopoiesis involves abnormal expansion of hematopoietic stem cells with leukemia-associated mutations.
  • It is more frequent with aging, genotoxic stress, and in individuals with existing lymphoid or solid tumors.

Purpose of the Study:

  • To examine the clinical implications of clonal hematopoiesis in cancer patients.
  • To discuss strategies for mitigating adverse consequences of clonal expansion in this population.

Main Methods:

  • Literature review and synthesis of existing research on clonal hematopoiesis in the cancer setting.
  • Analysis of potential mechanisms linking clonal hematopoiesis to adverse outcomes.

Main Results:

More Related Videos

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.8K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.7K

Related Experiment Videos

Last Updated: Dec 28, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.8K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.8K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.7K
  • Clonal hematopoiesis elevates the risk of therapy-related myeloid neoplasms.
  • It contributes to poor cancer survival via bone marrow microenvironment alterations, inflammation, and immune modulation.

    • Conclusions:

    • Clonal hematopoiesis significantly impacts cancer patient outcomes, particularly concerning therapy-related myeloid neoplasms.
    • Further understanding is crucial for developing effective screening, surveillance, and targeted therapeutic strategies.